Patent: 8,273,721

Summary for Patent: 8,273,721

Title:	Combination treatment for bladder cancer
Abstract:	Novel methods useful for treating a patient with bladder cancer such as superficial bladder cancer includes administering to the patient a therapeutically effective amount of valrubicin and trospium chloride.
Inventor(s):	Shipley; James E. (Lexington, MA)
Assignee:	Endo Pharmaceuticals Solutions Inc. (Chadds Ford, PA)
Application Number:	12/397,831
Patent Claims:	see list of patent claims

US Patent 8,273,721: What the Claims Cover and How the Landscape Likely Looks

US 8,273,721 claims a combination approach for bladder cancer treatment that pairs valrubicin with trospium chloride plus a mucin-degrading enzyme selected from trypsin or hyaluronidase (including animal or recombinant human forms). The claims cover (i) a treatment method, (ii) multiple administration schedules and routes, and (iii) pharmaceutical compositions with defined concentration ranges.

This portfolio is not a “new drug” patent in the classic sense. It is a combination method/composition patent focused on co-delivery or sequenced delivery of established drug entities (valrubicin and trospium) with mucolytic/penetration-enhancing enzymes intended to improve drug activity at bladder tumor sites.

Core claim elements (from the claim set provided)

Claim cluster	Required elements	What is added/controlled
Method (independent claim 1)	Treat bladder cancer by administering a therapeutically effective amount of valrubicin, trospium chloride, and a mucin-degrading enzyme (trypsin or hyaluronidase)	Treating “bladder cancer” broadly; enzyme choice limited to two classes
Administration timing (claims 2-3)	Same as claim 1	Concomitant vs sequential administration
Route (claims 4-7)	Same as claim 1	Parenteral valrubicin vs enteral trospium; includes mixed routes
Formulation concentration (claim 8, 13)	Same as claim 1/12	Combined dosage form with ~5 to 100 mg/mL for each component
Procedure (claim 9)	Same as claim 1	Requires transurethral resection (TUR) prior to administration
Indication narrowing (claims 10-11)	Same as claim 1	Targets superficial bladder cancer and/or carcinoma in situ (CIS)
Composition (claim 12)	Composition with therapeutically effective amounts of valrubicin (or salt), trospium chloride, and enzyme (trypsin/hyaluronidase)	“Optionally carrier” breadth
Composition concentration (claim 13)	Same as claim 12	~5 to 100 mg/mL ranges
Enzyme specification (claims 14-16, 17)	Same as claim 1/12	Enzyme can be animal hyaluronidase or human recombinant hyaluronidase
Carrier (claim 18)	Same as claim 12	Saline as carrier

What the claims actually “buy” in scope and enforceability

1) The claim pivot is the enzyme triad: trypsin or hyaluronidase

The novelty wedge is the requirement that the regimen includes a mucin-degrading enzyme comprising trypsin or hyaluronidase. That is the single most constraining element across the method and composition claims.

This matters because it means:

• A product that combines valrubicin + trospium without a mucin-degrading enzyme is outside the claim language.
• A regimen using an enzyme outside the specified set (other proteases, other mucolytics, other glycosidases) risks non-infringement on the face of the claims.

2) Trospium chloride is not optional; route is constrained in several claims

The claims repeatedly require trospium chloride. Claims 6-7 also tie trospium administration to enteral (as written), while valrubicin is parenteral in several dependent claims.

Those route-dependent claims increase coverage for formulations and protocols that use:

• valrubicin via a systemic/parenteral approach, and
• trospium via enteral administration.

If, in practice, trospium is delivered intravesically with valrubicin or both are administered via the same route, the route-specific dependent claims may be harder to land, but the independent claim 1 still captures the regimen if the route does not limit infringement outside the dependent claim scopes.

3) Timing and co-formulation create overlapping infringement pathways

• Claims 2 and 3 create explicit protection for both concomitant and sequential administration.
• Claims 8 and 13 create explicit protection for a combined dosage form with defined ranges.

In practice, this is a risk-spreading strategy: infringement can occur whether the components are blended into a single formulation (claim 8/13) or administered in a staged protocol (claim 2/3).

4) The “TUR prior to administration” limitation can narrow method coverage

Claim 9 adds a procedural prerequisite. That is typical when the specification supports that clinical workflow. But it also means a method conducted without TUR may avoid claim 9 even if it still satisfies claim 1.

5) Indication narrowing focuses on superficial bladder cancer and CIS

Claims 10 and 11 limit to:

• superficial bladder cancer
• carcinoma in situ of urinary bladder

Those dependent claims likely track the label or study population supported in the patent. If competitors aim at muscle-invasive disease or other histologies, the dependent claims may be harder to invoke, while claim 1 still remains broader as written.

How to read the “5 to 100 mg/mL” ranges for design-around risk

Claims 8 and 13 require both valrubicin and trospium chloride to fall within about 5 to 100 mg/mL in the combined dosage form.

For enforcement, the key issues typically become:

• How “about” is construed relative to actual manufacturing concentrations.
• Whether alternative presentations (different unit dosing, different concentrations) are meaningfully outside the range.
• Whether a clinician can avoid infringement by using separate vials (separate dosage forms) even if the total amounts administered are therapeutically effective.

The method claims (1-7, 9-11) are not explicitly concentration-bounded, while the composition claims are. So a competitor aiming for safety in formulation space may still face exposure under claim 1 even if it changes concentrations, unless it removes the enzyme element or changes the essential administration framework.

Critical assessment of claim strength vs likely prior art

Likely invalidity pressure: combination-of-knowns and routine pairing

Even with a precise claim structure, combination patents can face obviousness pressure if:

• valrubicin was already used in bladder cancer therapy,
• trospium chloride was already used to modulate drug delivery (for example, anticholinergic effects or formulation stability roles),
• mucin-degrading enzymes were already studied as penetration enhancers or mucolytics in urinary tract or similar delivery contexts,
• and the combination was an obvious attempt to improve local drug exposure.

The legal analysis will hinge on whether the prior art disclosed:

• the same therapeutic objective (improved local retention or penetration into bladder lesions),
• the same components in the same combination,
• and any evidence of unexpected results attributable to the combined use.

Because the claim set is written around a straightforward triad (valrubicin + trospium + trypsin/hyaluronidase), it is structurally vulnerable if the literature already described using mucin-degrading enzymes with bladder instillation of cytotoxic agents.

Likely patentability pressure: broad “bladder cancer” and flexible route language

• Claim 1 covers “bladder cancer” without limiting to non-muscle invasive disease in the independent claim.
• Dependent claims narrow to superficial and CIS, but a broad independent claim can increase invalidity exposure if prior art covered the drug combination in a subset of bladder cancer.

Likely enforceability issue: route terms (“parenterally” vs “enterally”)

The dependent claims impose route constraints in potentially non-standard terms for urinary instillation workflows. If the practical clinical protocol uses intravesical instillation for both components, the “parenteral” and “enteral” descriptors may create interpretive friction. That can affect enforcement strategy even if claim 1 remains broad.

Patent landscape: what this implies for competitors and investors

How competitors can fall into four practical zones

Competitor approach	Claim 1 enzyme element	Claim 8/13 concentration element	Overall exposure posture
Use valrubicin + trospium + trypsin/hyaluronidase	Yes	Depends on combined dosing	High exposure across independent and composition claims
Use valrubicin + trospium only (no trypsin/hyaluronidase)	No	Can be avoided by formulation anyway	Low exposure to this patent’s claims
Use valrubicin + trospium + different mucolytic/enzyme	“Wrong” enzyme	Depends	Reduced exposure, likely non-infringing on literal language
Use valrubicin + trospium + correct enzyme but change combined dosage concentration or blend into separate dosage forms	Yes	Possibly avoided for composition claims	Still potential exposure under method claims 1-7 (concomitant/sequential)

Where the most meaningful freedom-to-operate bottleneck likely sits

For any program targeting bladder cancer with valrubicin-like anthracycline-based cytotoxic activity, the real checkpoint is whether the developer:

• also includes a mucin-degrading enzyme from the specific set (trypsin or hyaluronidase), and
• uses a protocol that matches the timing (concomitant/sequential) and administration structure.

If both are yes, this patent becomes a major barrier even if formulation concentrations are adjusted.

Actionable claim-by-claim infringement focus

Method claims (1-11)

1. Independent claim 1: Treat bladder cancer with valrubicin + trospium chloride + trypsin/hyaluronidase (therapeutically effective amounts).
2. Dependent claim 2: Concomitant administration of valrubicin and trospium.
3. Dependent claim 3: Sequential administration of valrubicin and trospium.
4. Dependent claim 4: Valrubicin and trospium parenterally (as written in the claim set, note claim 7 nuance).
5. Dependent claim 5: Valrubicin parenterally.
6. Dependent claim 6: Trospium enterally.
7. Dependent claim 7: Valrubicin parenterally + trospium enterally.
8. Dependent claim 9: TUR prior to administration.
9. Dependent claim 10: Superficial bladder cancer.
10. Dependent claim 11: Carcinoma in situ.

Composition claims (12-18)

12. Independent composition claim: valrubicin (or salt) + trospium chloride + trypsin/hyaluronidase + optional carrier.
13. Dependent concentration range: ~5 to 100 mg/mL for both valrubicin and trospium in the combined dosage form. 14-16. Dependent enzyme identity: trypsin; animal hyaluronidase; human recombinant hyaluronidase.
14. “New pharmaceutical composition” with trypsin enzyme.
15. Carrier: saline.

Key Takeaways

• US 8,273,721 claims a tri-component bladder cancer regimen: valrubicin + trospium chloride + a mucin-degrading enzyme (trypsin or hyaluronidase).
• The independent method claim 1 is broad on indication (“bladder cancer”) and does not bind concentration, while dependent claims narrow indication (superficial bladder cancer, CIS), add procedural sequencing (TUR), and constrain timing/route.
• Composition claims 12-13 add defined concentration ranges (~5 to 100 mg/mL) for both valrubicin and trospium chloride, creating a more design-around-friendly path for formulation concentration but not for removing the enzyme requirement.
• The landscape risk for competitors is highest if they preserve the enzyme triad; design-around strategies that remove or swap the specified mucin-degrading enzyme are the most direct path to avoid literal coverage.

FAQs

1) What is the single most important limitation in the patent’s claims?
The regimen must include a mucin-degrading enzyme comprising trypsin or hyaluronidase.

2) Do the claims cover both concomitant and sequential dosing?
Yes. Claims 2 and 3 explicitly cover concomitant and sequential administration of valrubicin and trospium.

3) Do the composition claims require specific concentrations?
Yes. Claims 8 and 13 require a combined dosage form with about 5 to 100 mg/mL of valrubicin and about 5 to 100 mg/mL of trospium chloride.

4) Does claim 9 require a procedure before drug administration?
Yes. Claim 9 adds a limitation requiring transurethral resection (TUR) prior to administration.

5) Can a competitor avoid composition-claim exposure by changing formulation concentration?
It may reduce exposure to claims 8 and 13, but it does not remove risk under method claim 1 unless the enzyme triad or essential administration structure is also changed.

References

1. US Patent 8,273,721 (claim text provided by user).

Details for Patent 8,273,721

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2029-03-04
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2029-03-04
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2029-03-04
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005		2029-03-04
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859	December 02, 2005		2029-03-04
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	June 22, 2017		2029-03-04